 Busulfan
"Busulfan" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An alkylating agent having a selective immunosuppressive effect on BONE MARROW. It has been used in the palliative treatment of chronic myeloid leukemia (MYELOID LEUKEMIA, CHRONIC), but although symptomatic relief is provided, no permanent remission is brought about. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), busulfan is listed as a known carcinogen.
| Descriptor ID |
D002066
|
| MeSH Number(s) |
D02.033.455.125.125 D02.455.326.146.100.050.500.100 D02.886.645.600.055.050.510.100
|
| Concept/Terms |
Busulfan Wellcome- Busulfan Wellcome
- Wellcome, Busulfan
- Wellcome Brand of Busulfan
- Busulfan Wellcome Brand
Busulfex- Busulfex
- Orphan Brand of Busulfan
- Busulfan Orphan Brand
Myleran- Myleran
- Glaxo Wellcome Brand of Busulfan
- GlaxoSmithKline Brand of Busulfan
- Busulfan GlaxoSmithKline Brand
- Myléran
|
Below are MeSH descriptors whose meaning is more general than "Busulfan".
Below are MeSH descriptors whose meaning is more specific than "Busulfan".
This graph shows the total number of publications written about "Busulfan" by people in this website by year, and whether "Busulfan" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1984 | 0 | 1 | 1 | | 1992 | 1 | 0 | 1 | | 1993 | 0 | 1 | 1 | | 1995 | 0 | 1 | 1 | | 1996 | 0 | 1 | 1 | | 1997 | 1 | 0 | 1 | | 1999 | 1 | 0 | 1 | | 2001 | 0 | 1 | 1 | | 2003 | 1 | 1 | 2 | | 2005 | 0 | 1 | 1 | | 2008 | 0 | 2 | 2 | | 2010 | 1 | 0 | 1 | | 2012 | 1 | 0 | 1 | | 2013 | 1 | 1 | 2 | | 2014 | 2 | 1 | 3 | | 2015 | 0 | 2 | 2 | | 2017 | 1 | 0 | 1 | | 2019 | 1 | 0 | 1 | | 2020 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Busulfan" by people in Profiles.
-
Hsu J, Van Besien K, Baron F. Busulfan or melphalan: is there a better conditioning regimen for allogeneneic transplantation? Leuk Lymphoma. 2020 07; 61(7):1529-1534.
-
Schofield RC, Landau HJ, Giralt SA, Shah GL, Scordo M, Lin A, Zanutto E, Ramanathan LV, Pessin MS, Carlow DC. Measurement of the DNA alkylating agents busulfan and melphalan in human plasma by mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2019 Sep 01; 1125:121711.
-
Strouse C, Zhang Y, Zhang MJ, DiGilio A, Pasquini M, Horowitz MM, Lee S, Ho V, Ramanathan M, Chinratanalab W, Loren A, Burns LJ, Artz A, Villa KF, Saber W. Risk Score for the Development of Veno-Occlusive Disease after Allogeneic Hematopoietic Cell Transplant. Biol Blood Marrow Transplant. 2018 10; 24(10):2072-2080.
-
Harris AC, Boelens JJ, Ahn KW, Fei M, Abraham A, Artz A, Dvorak C, Frangoul H, Freytes C, Gale RP, Hong S, Lazarus HM, Loren A, Mineishi S, Nishihori T, O'Brien T, Williams K, Pasquini MC, Levine JE. Comparison of pediatric allogeneic transplant outcomes using myeloablative busulfan with cyclophosphamide or fludarabine. Blood Adv. 2018 06 12; 2(11):1198-1206.
-
Kebriaei P, Anasetti C, Zhang MJ, Wang HL, Aldoss I, de Lima M, Khoury HJ, Sandmaier BM, Horowitz MM, Artz A, Bejanyan N, Ciurea S, Lazarus HM, Gale RP, Litzow M, Bredeson C, Seftel MD, Pulsipher MA, Boelens JJ, Alvarnas J, Champlin R, Forman S, Pullarkat V, Weisdorf D, Marks DI. Intravenous Busulfan Compared with Total Body Irradiation Pretransplant Conditioning for Adults with Acute Lymphoblastic Leukemia. Biol Blood Marrow Transplant. 2018 04; 24(4):726-733.
-
Mohamed SA, Shalaby SM, Abdelaziz M, Brakta S, Hill WD, Ismail N, Al-Hendy A. Human Mesenchymal Stem Cells Partially Reverse Infertility in Chemotherapy-Induced Ovarian Failure. Reprod Sci. 2018 01; 25(1):51-63.
-
Pasquini MC, Le-Rademacher J, Zhu X, Artz A, DiPersio J, Fernandez HF, Mineishi S, Kamishohara M, Mehta J, Nakamura Y, Ratanatharathorn V, Sobecks R, Burkart J, Bredeson C. Intravenous Busulfan-Based Myeloablative Conditioning Regimens Prior to Hematopoietic Cell Transplantation for Hematologic Malignancies. Biol Blood Marrow Transplant. 2016 08; 22(8):1424-1430.
-
Anur P, Friedman DN, Sklar C, Oeffinger K, Castiel M, Kearney J, Singh B, Prockop SE, Kernan NA, Scaradavou A, Kobos R, Curran K, Ruggiero J, Zakak N, O'Reilly RJ, Boulad F. Late effects in patients with Fanconi anemia following allogeneic hematopoietic stem cell transplantation from alternative donors. Bone Marrow Transplant. 2016 Jul; 51(7):938-44.
-
Devine SM, Owzar K, Blum W, Mulkey F, Stone RM, Hsu JW, Champlin RE, Chen YB, Vij R, Slack J, Soiffer RJ, Larson RA, Shea TC, Hars V, Sibley AB, Giralt S, Carter S, Horowitz MM, Linker C, Alyea EP. Phase II Study of Allogeneic Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission Using a Reduced-Intensity Conditioning Regimen: Results From Cancer and Leukemia Group B 100103 (Alliance for Clinical Trials in Oncology)/Blood and Marrow Transplant Clinical Trial Network 0502. J Clin Oncol. 2015 Dec 10; 33(35):4167-75.
-
Geyer MB, Radhakrishnan K, Giller R, Umegaki N, Harel S, Kiuru M, Morel KD, LeBoeuf N, Kandel J, Bruckner A, Fabricatore S, Chen M, Woodley D, McGrath J, Baxter-Lowe L, Uitto J, Christiano AM, Cairo MS. Reduced Toxicity Conditioning and Allogeneic Hematopoietic Progenitor Cell Transplantation for Recessive Dystrophic Epidermolysis Bullosa. J Pediatr. 2015 Sep; 167(3):765-9.e1.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|